

Commercial/Healthcare Exchange PA Criteria

Effective: October 1, 2020

Prior Authorization: naproxen extended-release

Products Affected: naproxen 375mg extended-release oral tablet, naproxen sodium 500mg controlled-release oral tablet, Naproxen sodium CR 750mg oral tablet, Naproxen Sodium ER 750mg Tablet

Medication Description: Naproxen reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties.

Covered Uses:

1. Treatment of rheumatoid arthritis
2. Treatment of osteoarthritis
3. Treatment of ankylosing spondylitis
4. Treatment of tendinitis, bursitis
5. Treatment of acute gout
6. Treatment of primary dysmenorrhea
7. Relief of mild to moderate pain

Exclusion Criteria:

1. Known hypersensitivity to naproxen
2. History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs
3. In the setting of coronary artery bypass graft (CABG) surgery

Required Medical Information:

1. Diagnosis
2. Medical History
3. Previous therapies tried and failed

Age Restrictions: 18 years of age and older

Prescriber Restrictions: None

Coverage Duration: 12 months

Other Criteria:

- A. Patient has one of the following conditions:
 - a. Rheumatoid arthritis
 - b. Osteoarthritis
 - c. Ankylosing spondylitis
 - d. Tendinitis, bursitis
 - e. Acute gout

- f. Primary dysmenorrhea
- g. Mild to moderate pain; **AND**

B. Patient has had a trial and failure, intolerance, or contraindication to at least TWO other generic NSAIDs (e.g. diclofenac potassium 50mg, diclofenac sodium (oral) 25mg, 50mg, 75mg, ibuprofen (Rx) 600mg, 800mg, nabumetone 500mg, 750mg, or naproxen immediate release (Rx) 375mg, 500mg.)

References:

1. Naprelan controlled release tablets (naproxen) [prescribing information]. Morristown, NJ: Almatica Pharma, Inc.; July 2019.

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	10/1/2020
2	Update	Added Naproxen sodium CR 750mg oral tablet to products affected	Products affected	2/2/2021
3	Update	Added Naproxen Sodium ER 750mg Tablet to Products Affected	Products Affected	12/7/2022